Abstract
COVID-19 pandemic has devasted world since December 2019 Many countries being affected by the deadly virus has implemented lockdown to slowdown the spread of virus As the disease condition is new to everyone many experimental drugs are being introduced Hydroxychloroquine considered to be found to be not effective Then drug which were originally used as antiviral agents such as disease treatment Favipiravir is RNA dependent RNA polymerase inhibitor which commonly used in Avian flu to control disease spread found to be effective aid in the Novel COVID-19 disease conditions In this study we have compared two marketed different tablets of FAvipiravir for their dissolution studies Dissolution studies were done simultaneously to avoid errors Tablets was found to be immediate release The percent drug release for fabiflu is 113 84 and percent drug release for Fviflow is 127 91 The Fabiflu tablet has shown reliable dissolution profile compared to the Faviflow tablets and found to be within limits
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
